Seshu Tyagarajan Sells 31,278 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 31,278 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $8.82, for a total transaction of $275,871.96. Following the transaction, the chief technology officer now owns 85,512 shares in the company, valued at approximately $754,215.84. The trade was a 26.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Seshu Tyagarajan also recently made the following trade(s):

• On Wednesday, January 15th, Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock. The shares were sold at an average price of $7.22, for a total transaction of $103,404.84.

Candel Therapeutics Trading Down 7.3 %

CADL stock opened at $8.25 on Friday. Candel Therapeutics, Inc. has a twelve month low of $1.40 and a twelve month high of $14.60. The company has a market capitalization of $267.93 million, a P/E ratio of -4.77 and a beta of -1.29. The firm has a 50 day simple moving average of $8.22 and a 200-day simple moving average of $7.00.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17). On average, research analysts predict that Candel Therapeutics, Inc. will post -1.47 EPS for the current year.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors have recently modified their holdings of CADL. BNP Paribas Financial Markets bought a new position in Candel Therapeutics in the fourth quarter worth about $30,000. Russell Investments Group Ltd. raised its position in shares of Candel Therapeutics by 75.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company’s stock worth $33,000 after purchasing an additional 1,610 shares during the period. FMR LLC bought a new stake in shares of Candel Therapeutics in the 3rd quarter worth approximately $46,000. MetLife Investment Management LLC acquired a new position in Candel Therapeutics during the 3rd quarter valued at approximately $87,000. Finally, Wells Fargo & Company MN grew its stake in Candel Therapeutics by 63.6% during the 4th quarter. Wells Fargo & Company MN now owns 10,122 shares of the company’s stock worth $88,000 after buying an additional 3,935 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.

Analyst Upgrades and Downgrades

CADL has been the subject of several recent research reports. Canaccord Genuity Group increased their price objective on shares of Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Candel Therapeutics in a research report on Friday, March 14th. Citigroup initiated coverage on shares of Candel Therapeutics in a research report on Thursday, February 20th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Bank of America initiated coverage on shares of Candel Therapeutics in a research report on Friday, February 7th. They issued a “buy” rating and a $15.00 price objective for the company.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.